SCHEMBL147803

SCHEMBL147803

OCc1cc[c]c(F)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1662135 0.83 KDM4E (0.42)
SCHEMBL1663606 0.78 TRPA1 (0.31)
SCHEMBL21194005 0.77
SCHEMBL61982 0.77
SCHEMBL2052825 0.75 ALOX15 (0.33)
SCHEMBL22344571 0.75 AKR1B1 (0.48)
SCHEMBL1661697 0.75 S1PR1 (0.33)
SCHEMBL1663636 0.75 PCNA (0.36)
SCHEMBL5504193 0.74
SCHEMBL28116640 0.74 TSHR (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2532663-B1 Naphthalenetetracarboxylic acid derivatives and their use as semiconductors BASF SE (DE) 2016-03-16 EP claimed
EP-2306994-B1 S1P1 RECEPTOR AGONISTS AND USE THEREOF AMGEN INC (US) 2013-08-14 EP claimed
US-8367673-B2 Substituted diketopiperazines as oxytocin antagonists GLAXO GROUP LIMITED (GB) 2013-02-05 US claimed
EP-2532663-A1 Naphthalenecarboxylic acid derivatives and their use as semiconductors BASF SE (DE) 2012-12-12 EP claimed
JP-2011524906-A 2011-09-08 JP claimed
EP-2306994-A1 S1P1 RECEPTOR AGONISTS AND USE THEREOF Amgen, Inc (US) 2011-04-13 EP claimed
US-7842685-B2 S1P1 receptor agonists and use thereof AMGEN INC. (US) 2010-11-30 US claimed
US-20100029611-A1 S1P1 receptor agonists and use thereof AMGEN INC. (US) 2010-02-04 US claimed
WO-2009154775-A1 S1P1 RECEPTOR AGONISTS AND USE THEREOF AMGEN INC. (US) 2009-12-23 WO claimed
US-20090186867-A1 Substituted Diketopiperazines As Oxytocin Antagonists GLAXO GROUP LIMITED 2009-07-23 US claimed
US-7514437-B2 Substituted diketopiperazines as oxytocin antagonists SMITHKLINE BEECHAM CORP. (US) 2009-04-07 US claimed
EP-1458393-B1 SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS GLAXO GROUP LTD (GB) 2008-06-25 EP claimed
CN-100374115-C Substituted diketopiperazines as oxytocin antagonists GLAXO GROUP LTD (GB) 2008-03-12 CN claimed
US-20050148572-A1 Substituted diketopiperazines as oxytocin antagonists GLAXO GROUP LIMITED (GB) 2005-07-07 US claimed
CN-1606443-A Substituted diketopiperazines as oxytocin antagonists GLAXO GROUP LTD (GB) 2005-04-13 CN claimed
WO-2005000311-A1 SUBSTITUTED DIKETOPIPERAZINES FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA GLAXO GROUP LIMITED (GB) 2005-01-06 WO claimed
EP-1458393-A1 SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS GLAXO GROUP LIMITED (GB) 2004-09-22 EP claimed
WO-2003053443-A1 SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS GLAXO GROUP LIMITED (GB) 2003-07-03 WO claimed
US-20230303608-A1 DITHIOLENE METAL COMPLEXES BASF SCHWEIZ AG (CH) 2023-09-28 US disclosed
WO-2003053443-A1 SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS GLAXO GROUP LIMITED (GB) 2003-07-03 WO disclosed